SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 16.01 |
| Enterprise Value ($M) | 17.21 |
| Book Value ($M) | 37.50 |
| Book Value / Share | 2.53 |
| Price / Book | 0.43 |
| NCAV ($M) | 7.12 |
| NCAV / Share | 0.48 |
| Price / NCAV | 2.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.04 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -0.05 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.25 |
| Current Ratio | 2.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16.93 |
| Assets | 47.32 |
| Liabilities | 9.81 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 37.33 |
| Operating Income | -0.20 |
| Net Income | -1.86 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -0.96 |
| Cash from Investing | -0.48 |
| Cash from Financing | -0.77 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| LABFF – Laboratorios Farmaceuticos Rovi, S.A. | LADX – LadRx Corporation |
| LBTSF – Almirall, S.A. | LIFS – Life Stem Genetics Inc. |
| LSDIF – Lucy Scientific Discovery Inc. |
Financial data and stock pages provided by
Fintel.io